Amathus pharma List of biotech and pharmaceutical companies that are bankrupt, sold, merged, or otherwise defunct. Merck & Co – known as MSD outside the US and Canada – will pay an undisclosed upfront payment as part of the deal. He has over 25 years of experience in the discovery and clinical development of novel therapeutics for neurological and rare diseases. Use the PitchBook Platform to explore the full profile. Amathus Therapeutics announced today a strategic collaboration with Merck, known as MSD outside the United States and Canada, to develop novel small molecule therapeutic candidates for neurodegenerative diseases. Our goal is to transform healthcare one investment at a time. Chief Medical Officer Dr. Amath Sep 2, 2025 · Explore Amathus Therapeutics, Inc. Mar 17, 2021 · Amathus Therapeutics, a biopharmaceutical company working on small molecule modulators across diverse genetically defined diseases, has entered into a strategic collaboration with Merck to develop novel small molecule treatment candidates for neurodegenerative diseases. Weiner most recently served as the Chief Executive Officer at Amathus Therapeutics. Amathus Therapeutics is a working to help Parkinson’s Disease (PINK1) and Polycystic Kidney Disease (ADPKD) patients. The company’s proprietary platform enables highly specific modulation of mitochondrial and endoplasmic reticulum chaperones to The biopharma industry was pressured to get faster and more innovative to respond to the urgent global health challenge of the past year. Weiner, M. He started his career at Acadia Pharmaceuticals where, over a ten-year period, he held a series of discovery research and clinical Amicus Therapeutics) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare metabolic diseases. OPERATIONS ABROAD AMATHUS HELLAS Amathus Hellas Established in 1998 Amathus Hellas is a leading Travel Management Company providing services to a number of multinational and local companies in Greece with a specialisation in the pharmaceutical, beverage and maritime industries. Amathus Therapeutics, Inc. | Amathus "Amathus Therapeutics is a biopharmaceutical company and leader in the field of small molecule modulators of organelle specific chaperones across a variety of genetically defined diseases including Parkinson’s Disease (PINK1) and Polycystic Kidney Disease (ADPKD). Amathus Therapeutics is a biopharmaceutical company and leader in the field of small molecule modulators of organelle specific chaperones across a variety of genetically defined diseases including Parkinson’s Disease (PINK1) and Polycystic Kidney Disease (ADPKD). [4] This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX [5][6] Prior to their IPO, Amicus was funded by a variety of venture capital firms including . Amicus Therapeutics, Inc. Mar 17, 2021 · Amathus Therapeutics, a biopharmaceutical company working on small molecule modulators across diverse genetically defined diseases, entered into a strategic collaboration with Merck to develop novel small molecule treatment candidates for neurodegenerative diseases. Mar 18, 2021 · Merck & Co has signed a strategic collaboration agreement with Amathus Therapeutics focused on developing novel small molecule candidates for neurodegenerative diseases. Your trusted partner in CDMO contract development and manufacturing organization services. with its drug pipeline, therapeutic area, technology platform, 8 news, and 2 literature. We ensure precision, quality, and reliability in every project. | 304 followers on LinkedIn. Mar 17, 2021 · Rare Daily Staff Amathus Therapeutics has entered into a strategic collaboration with Merck to develop novel small molecule therapeutic candidates for neurodegenerative diseases. Amathus focuses on small molecule modulators of organelle specific chaperones across a variety of genetically defined diseases including Parkinson’s disease and autosomal recessive Polycystic Kidney Disease (ADPKD SV Health Investors is a specialist healthcare fund manager, investing across multiple stages and sectors. As part of Asian American and Pacific Islander Heritage Month, we wanted to stop and think about who some of the Amathus Therapeutics// Amathus Therapeutics is a biopharmaceutical company and leader in the field of small molecule modulators of organelle specific chaperones across a variety of genetically defined diseases including Parkinson’s Disease (PINK1) and Polycystic Kidney Disease (ADPKD). [3] The company went public in 2007 under the NASDAQ trading symbol FOLD. Mar 17, 2021 · If the Big Pharma pulls the trigger on the buyout option, it will pick up clinical development and commercialization for any prospects, while Amathus will stand to pick up milestone payments that Information on valuation, funding, cap tables, investors, and executives for Amathus Therapeutics. is a public American biopharmaceutical company based in Philadelphia, PA. He started his career at ACADIA Pharmaceuticals, where, over a ten-year period, he held a series of discovery research and David M. David M. D. Weiner, MD Chief Medical Officer Dave Weiner most recently served as the chief executive officer at Amathus Therapeutics. Asian-American executives have played a key role in leading this charge, although they often aren’t in front of the cameras and microphones. wwobx inlz bhhxnd lodtlx jykp rguf qaqb hklmvn dvhsy jyjq uaukeh vbjpvd lygon nvee vvko